Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

49.36 -0.40 (-0.80%)
Streaming Delayed Price Updated: 10:45 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
TG Therapeutics Q2 Earnings Call Highlights ↗
TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company... 
Via MarketBeat
Topics Earnings
TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth ↗
Via Chartmill
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength ↗
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates ↗
Via Chartmill
Topics Earnings
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside ↗
Via Chartmill
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum ↗
Via Chartmill
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
TG Therapeutics Stock Surges After Drug Trial Update ↗
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation. 
Via Benzinga
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup ↗
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook ↗
Via Chartmill
Topics Earnings
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally ↗
Via Stocktwits
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. 
Via The Motley Fool
News headline image
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript ↗
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
TGTX Q1 2025 Earnings Call Transcript ↗
TGTX Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology. 
Via The Motley Fool
News headline image
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript ↗
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
News headline image
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' ↗
TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression. 
Via Stocktwits
News headline image
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares ↗
This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline. 
Via The Motley Fool
News headline image
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 ↗
The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S. 
Via Stocktwits
Topics Artificial Intelligence
These stocks are moving in today's after hours session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.